Aptose Biosciences Inc.
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
Ontario, Canada
Country
Ontario, Canada
Business Address
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ,
Mailing Address
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ,
Phone
310-849-8060
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$2.90M
Stockholders' Equity
$-10.41
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 8-K Current report of material events | February 24, 2026 | View on SEC |
| 8-K Current report of material events | December 19, 2025 | View on SEC |
| 8-K Current report of material events | December 8, 2025 | View on SEC |
| 8-K Current report of material events | November 25, 2025 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Aptose Biosciences has entered a definitive agreement to be acquired by Hanmi Pharmaceutical for C$115 million.
- Shareholders are set to receive C$2.41 in cash per share upon the successful closing of the acquisition.
Material Events
8-K
Acquisition
March 23, 2026
High Impact
- Hanmi Pharmaceutical is acquiring Aptose Biosciences for $0.30 per share in cash.
- The acquisition price represents a significant premium over Aptose's pre-announcement trading price.
8-K
Acquisition
March 19, 2026
High Impact
- ISS (Institutional Shareholder Services) has recommended approval of the acquisition, significantly increasing its likelihood.
- Hanmi Pharmaceutical, a major South Korean drug company, is acquiring Aptose Biosciences Inc., making it a private entity.
Related Companies
Companies in the same industry (SIC: 2836)
Kodiak Sciences Inc.
KOD
Biological Products, (No Diagnostic Substances)
BioAtla, Inc.
BCAB
Biological Products, (No Diagnostic Substances)
Cardiff Oncology, Inc.
CRDF
Biological Products, (No Diagnostic Substances)
HALOZYME THERAPEUTICS, INC.
HALO
Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corp
ADPT
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.